Microbial transglutaminase for biotechnological and biomedical engineering

Area of Science:

• Biochemistry
• Enzymology
• Biotechnology

Background:

• Microbial transglutaminase (MTG) was isolated in 1989 from Streptomyces mobaraensis.
• Initially identified for cost reduction in food manufacturing, MTG's robustness and ease of handling made it valuable for biotech and pharma.
• Early applications focused on cross-linking, leading to heterogeneous polymers.

Purpose of the Study:

• To review the field of microbial transglutaminase-mediated bioconjugation, with an emphasis on pharmaceutical research.
• To highlight advancements in enzyme engineering, including directed evolution and rational design.
• To discuss limitations of MTG, such as substrate indiscrimination, and strategies to overcome them.

Main Methods:

• Literature review of microbial transglutaminase applications in bioconjugation.
• Analysis of enzyme engineering techniques (directed evolution, rational design).
• Discussion of strategies to address substrate promiscuity challenges.

Main Results:

• MTG is currently used for site-specific ligation of biomolecules, creating precisely modified hybrid constructs.
• Enzyme engineering has improved MTG's specificity and utility.
• Methods to bypass substrate indiscrimination have been developed.

Conclusions:

• Microbial transglutaminase is a powerful tool for creating complex biomolecular constructs in pharmaceutical research.
• Ongoing enzyme engineering efforts continue to expand MTG's capabilities.
• Addressing substrate limitations is key to maximizing MTG's potential in bioconjugation.